
2015/05/13 15:18 | |
|主訴(Chief Complaint)                                            |
|Informant:patient, family and medical record yellowish skin for  |
|one week                                                         |
|病史(Brief History)                                              |
|This 79-year-old man is a patient of 1. Metastatic gastric       |
|cancer, adenocarcinoma, intestinal type, Borrmann type III,      |
|moderately differentiated, with liver metastasis, stage IV,      |
|non-resectable, cT4N2M1, HER2/Neu 3+/3+ with increasing Ki-67    |
|activity, p53 negative, status post palliative chemotherapy      |
|cisplatin + capecitabine (IV) (2013/5/28-2013/7/30), progressive |
|disease, status post phase II/III study with TDM1 (VIII)         |
|(2013/8/30-2014/1/24), partial response (PR) then later with     |
|progressive disease (PD), status post LJM716+ Herceptin (VIII)   |
|(2014/2/25-2014/9/30), partial response (PR) then PD later, under|
|ASLAN001 plus Cisplatin and Capecitabine(V)                      |
|(2014/10/22~2015/02/04) 2. Herpes zoster on the right T10, healed|
|3. Anemia, transfusion required The initial presentation was     |
|progressive dyspnea for 6 months in 2013. Progressive poor       |
|appetite and early satiety were also noted for 2 months. He      |
|developed progressive dyspnea, dizziness and exertional          |
|intolerance. Body weight loss of 6kg/6months was also recalled   |
|(75kg to 69kg). He went to Cardinal Tien Hospital (耕莘) on      |
|2013/05/04. However, lab data showed severe anemia of 5.0 g/dL   |
|which may be the cause of his dyspnea, dizziness and exertional  |
|intolerance. Blood transfusion was performed. His dyspnea,       |
|dizziness and exertional intolerance improved gradually.         |
|Abdominal echo on 2013/5/6 showed an echogenic lesion 3.5cm near |
|the pancreatic head and panendoscopy on 2013/5/6 showed a        |
|protruding mass over 5cm with ulceration at gastric antrum       |
|posterior wall extended to lower gastric body. Biopsy on 2013/5/6|
|showed gastric adenocarcinoma, intestinal type, moderately       |
|differentiated, Bormann type 3. Abdominal CT on 2013/5/6 showed  |
|advanced gastric cancer, lower body and antrum, with extraserosal|
|invasion, multiple regional and paraaortic lymphadenopathy,      |
|multiple liver metastasis and suspecting local invasion of       |
|pancreatic head. He then came to NTUH for second opinion.        |
|Panendoscopy on 2013/05/20 showed fungating tumors from upper    |
|body to antrum, causing poor expansion of stomach and luminal    |
|stenosis status post biopsy which showed adenocarcinoma,         |
|Her-2/Neu 3+/3+, increasing ki-67 activity and p53 negative.     |
|Gastric cancer, cT4N2M1, HER2 (3+) was diagnosed. Port-A was     |
|implantation on 2013/5/22 for chemotherapy. He then received     |
|Capecitabine and Cisplatin for 4 cycles from 2013/5/28 to        |
|2013/7/30. However, followed up abdominal CT on 2013/8/9 showed  |
|disease progression with right adrenal metastasis and multiple   |
|lymph nodes metastasis (upper abdomen and bilateral paraaortic   |
|areas). Thus, he was enrolled into Phase II/III TDM1 trial (VIII)|
|from 2013/8/30 to 2014/1/24. Subsequent CT during the            |
|chemotherapy was stationary. The CEA level was elevated to 611.6 |
|ng/ml and CT scan on 2014/1/10 revealed advanced gastric cancer  |
|with prominent LAPs, liver and right adrenal metastases,         |
|enlarged. Then, he was enrolled another trial of LJM716+Herceptin|
|trial (VIII) form 2014/2/25 to 2014/9/30. The side effect was    |
|grade I-II diarrhea and grade I anorexia. The CT on 2014/2/11    |
|showed partial response. Then, following up frequency CT on      |
|20114/4/16, 2014/5/14, and 2014/6/11 showed 1.) gastric cancer   |
|with liver and adrenal metastases. 2.) abdominal lymphadenopathy,|
|stable disease. However, CT on 2014/8/6 and 2014/10/01 showed    |
|disease progression. Due to disease in progression with liver and|
|adrenal metastases, then he was enrolled into phase I trial with |
|ASLAN001 plus Cisplatin and Capecitabine (V) [ASLAN001 (100      |
|mg/1tab) 4 tabs PO BID on D1-D21 before Xeloda ; Capecitabine    |
|(500 mg/tab) 7 tab PO AS ORDER 9AM 4tabs PO QD; 6PM 3tabs PO QN  |
|(after ASLAN) on D1-D14; Cisplatin (80mg/m2) IF 2hrs on D1] from |
|2014/10/22 to 2014/2/04. Grade I~II mucositis was noted after    |
|treatment. Hypokalemia occurred and corrected later. The followed|
|CT scan on 2014/11/21 showed the size of gastric tumor was       |
|smaller but the size of right adrenal was larger than previous   |
|CT. He suffered from grade I mucositis, asthenia, diarrhea, and  |
|nausea. Due to elevation of ACTH (134 pg/ml), the urine free     |
|cortisol was checked and within normal limit. Second primary     |
|adrenal tumor was not favored and paraneoplastic syndrome was    |
|favored.He suffered from exertional dyspnea and intermittent     |
|dizziness in recent one month. He was admitted on 2015/03/10 for |
|phase I trial with ASLAN001 plus Cisplatin and Capecitabine      |
|treatment. After admission, Phase I trial ASLAN001 plus Cisplatin|
|and Capecitabine (VI) {ASLAN001 (100 mg/1tab) 4 tabs PO BID on   |
|D1-D21 before Xeloda ; Capecitabine (500 mg/tab) 7 tab PO AS     |
|ORDER 9AM 4tabs PO QD; 6PM 3tabs PO QN (after ASLAN) on D1-D14;  |
|Cisplatin (80mg/m2) IF 2hrs on D1}was given since 3/11. There was|
|no acute toxicity chemotherapy. He was discharged under stable   |
|condition and will be followed at OPD. C+A+P CT study on         |
|2015/05/01 revealed gastric cancer with enlarged abdominal       |
|lymphadenopathy, liver and right adrenal metastases. Biliary     |
|dilatation was also noted. Yellowish skin and sclera was noted in|
|recent one week, but there was no fever, abdominal pain,         |
|clay-color stool or tea-color urine. During regular OPD          |
|follow-up, lab data on 2015/05/11 disclosed elevation of         |
|bilirubin level (t-bil: 1.99 -> 11.45). This time, he was        |
|admitted for percutaneous transhepatic cholangial drainage       |
|(PTCD). Family History: denied GI malignancy Medication          |
|Allergy:UnClear 病人自述 2013/08/29 No 病人自述 2013/05/27 No 病 |
|人自述 2013/05/13 No 親屬描述 2015/05/13 No 病人自述 2015/01/06  |
|No 病人自述 2014/11/11 Medication ADR:unknown Allergy to Medical |
|Device and Materials:UnClear 病人自述 2013/08/29 No 病人自述     |
|2013/05/27 UnClear 病人自述 2013/05/13 No 病人自述 2015/01/06 No |
|親屬描述 2015/05/13 No 病人自述 2014/11/11 NTUH: see OPD         |
|medication 中草藥: nil 保健食品: nil Past Medical History:       |
|gastric cancer Hospitalization: 入院日期:2014_12_02 出院日期: 診 |
|斷:Gastric cancer 入院日期:2015_03_03 出院日期: 診斷:Gastric     |
|cancer 入院日期:2015_03_10 出院日期:2015_03_12 診斷:Gastric      |
|cancer 入院日期:2015_02_03 出院日期:2015_02_05 診斷:Gastric      |
|cancer 入院日期:2015_01_06 出院日期:2015_01_08 診斷:Gastric      |
|cancer 入院日期:2014_12_09 出院日期:2014_12_11 診斷:Gastric      |
|cancer 入院日期:2014_11_11 出院日期:2014_11_13 診斷:Gastric      |
|cancer 入院日期:2014_11_04 出院日期:2014_11_06 診斷:Gastric      |
|cancer 入院日期:2014_10_21 出院日期:2014_10_23 診斷:Gastric      |
|cancer 入院日期:2014_02_24 出院日期:2014_02_26 診斷:Gastric      |
|cancer 入院日期:2013_08_29 出院日期:2013_09_07 診斷:Gastric      |
|cancer 入院日期:2013_05_27 出院日期:2013_05_30 診斷:Gastric      |
|cancer Past Surgical History:2013_05_22 Port-A implantation,     |
|echo-guided Travel History: nil                                  |
|社會心理相關評估(Psychosocial Assessment)                        |
|Social Economic and Personal History 教育程度:國中 職業:退休     |
|宗教信仰:佛教 婚姻狀態:已婚 使用語言:國語 台語 口述血型:O，RH:不 |
|清楚，輸血反應:無 抽煙:沒有 喝酒:沒有 檳榔:沒有 物質濫用:沒有    |
|Psychological History and Evaluation 意識狀態:警醒 認知功能:正常 |
|精神情緒狀態:正常 安全問題:有 其他 跌倒 睡眠形態:正常 Nutritional|
|Screen 攝食情形:普通，攝食50-74% 排便狀態:正常 BMI:25.46 Fall    |
|Risk Assessment 總分:10 (>=3分進行不倒翁計畫，請開預防跌倒醫囑)  |
|系統性回顧(Review of System)                                     |
|1.Systemic: weight loss(-), easy-fatigability(-), night sweats(-)|
|2.Skin: petechiae(-), purpurae(-), skin rash(-), itching(-),     |
|3.HEENT: headache(-),dizziness(-), blurred vision(-),            |
|strabismus(-), ocular pain(-), otalgia(-), otorrhea(-), hearing  |
|impairment(-), tinnitus(-), vertigo(-), nasal stuffiness(-),     |
|nasal discharge(-), epistaxis(-), gum bleeding(-), sore          |
|throat(-),oral ulcer(-) 4.Cardiovascular: exertional chest       |
|tightness(-), nocturnal dyspnea(-), orthopnea(-) syncope(-),     |
|palpitation(-), intermittent claudication(-) 5.Respiratory:      |
|dyspnea(-), cough(-), chest pain(-), hemoptysis(-), productive   |
|cough (-), pleuritic chest pain(-) 6.Gastrointestinal:           |
|anorexia(-), nausea(-), vomiting(-), dysphagia(-), heartburn(-), |
|acid regurgitation(-), abdominal fullness(-), hunger pain(-)     |
|midnight pain(-), constipation(-), diarrhea(-), melena(-), change|
|of bowel habit(-), small caliber of stool(-), tenesmus(-),       |
|flatulence(-) 7.Urogenital: flank pain(-), hematuria(-), urinary |
|frequency(-), urgency(-), dysuria (-), hesitancy(-), small stream|
|of urine(-), impotence(-), nocturia(-), polyuria(-), oliguria (-)|
|8.Musculoskeletal: bone pain(-), arthralgia(-), myalgia(-),      |
|weakness(-) back pain(-) 9.Metabolic: heat intolerance(-), cold  |
|intolerance(-), thirsty(-) 10.Nervous: numbness (-),             |
|paresis/plegia (-)                                               |
|身體檢查(Physical Examination)                                   |
|BH:164.4 cm BW:68.8 kg T:36.7 P:100 R:20 BP:127/70 mmHg Pain:0   |
|Neurological Examination: . Consciousness: clear . Muscle power: |
|fair . Gait: not check Head-Eye-ENT grossly normal, conjunctiva: |
|pink, sclera: icteric(+) Pupil: isocoric, 3mm/ 3mm Light reflex: |
|L/R: +/+, EOM: full and free Neck Jugular vein engorgement(-)    |
|Thyroid goiter(-) Meningismus: Kernig sign(-); Brudzinski sign(-)|
|Carotid bruit(-) Chest Thoracic cage contour: symmetric Vocal    |
|fremitus and expansion: symmetric Percussion: resonant Breathing |
|sound: clear Crackles(-) wheezes(-)rhonchi(-) stridor(-) Heart   |
|Heart beat: regular Murmurs(-) LV lift(-) RV heave(-) Increased  |
|cardiac size by percussion(-) Adventitious sounds (-) Abdomen    |
|distended & soft Superficial vein engorgement(-) Protruded       |
|umbilicus(-) Bowel sound: Normoactive Tenderness(-)              |
|Hepato-jugular reflux(-) Liver and spleen: impalpable Extremities|
|Freely movable, pulses symmetric and intact, pitting edema(-)    |
|Back Knocking pain(-) Skin Abnormal pigmentation(-) Petechiae(-) |
|Purpura(-) Ecchymoses(-) Telangiectasia(-) Rash(-) Plaque(-)     |
|Lymphadenopathy(-)                                               |
|檢驗紀錄(Laboratory Report)                                      |
|*********檢驗室:HE*********** 群組:CBC+PLT WBC RBC HB HCT MCV    |
|time/item (k/μL) (M/μL) (g/dL) (%) (fL) 1040511 [0835] 9.72 2.54 |
|8.6 25.1 98.8 MCH MCHC PLT RDW-CV Retic. time/item (pg) (g/dL)   |
|(k/μL) (%) (%) 1040511 [0835] 33.9 34.3 235 17.5 6.40 PS         |
|Retic.No. IRF time/item () (10^4/μL) (%) 1040511 [0835] - 16.26  |
|32.4 （僅供參考） 群組:WBC D/C Blast Promyl. Myelo. Meta Band    |
|time/item (%) (%) (%) (%) (%) 1040511 [0835] 0.0 0.0 0.0 0.0 0.0 |
|Seg Eos. Baso. Mono. Lym. time/item (%) (%) (%) (%) (%) 1040511  |
|[0835] 72.4 0.6 0.1 9.8 17.1 Aty.Lym. PlasmaCell Normobl. PS     |
|time/item (%) (%) () () 1040511 [0835] 0.0 0.0 0 - *********檢驗 |
|室:BC*********** 群組:General BioChemistry Alb TP T-BIL AST ALT  |
|time/item (g/dL) (g/dL) (mg/dL) (U/L) (U/L) 1040511 [0835] 3.3   |
|6.2 11.45 107 69 ALP GGT UN CRE Na time/item (U/L) (U/L) (mg/dL) |
|(mg/dL) (mmol/L) 1040511 [0835] 127 480 13.2 1.1 134 K Cl Ca     |
|time/item (mmol/L) (mmol/L) (mmol/L) 1040511 [0835] 3.1 102 2.06 |
|群組:DM GLU AC time/item (mg/dL) 1040511 [0835] 113              |
|*********檢驗室:CT*********** 群組:PT PT PT INR time/item (sec)  |
|() 1040511 [0835] 14.2 1.34 群組:PTT PTT time/item (sec) 1040511 |
|[0835] 29.2 群組:Other Test Mixed APTT time/item (sec) 1040511   |
|[0835] 27.4(imm.)/2 8.0(1hr) *********檢驗室:OP***********       |
|群組:SEDIMENT RBC (S) WBC (S) Epith (S) Cast (S) Crystal (S)     |
|time/item (/HPF) (/HPF) (/HPF) (/LPF) (*) 1040511 [0906] 0-2 0-2 |
|0-2 Gr(10-20) - Bacteria Mucus(S) Others (S) time/item (*) (*)   |
|(*) 1040511 [0906] + - - 群組:MULTISTIX Sp. Gr.(C) pH Protein(C) |
|Glu.(C) Ketone body (U) time/item (*) (*) (mg/dL) (mg/dL) (*)    |
|1040511 [0906] 1.019 6.0 30 ( 1+ ) - - O.B.(C) Urobil.(C) Bil.(C)|
|Nitrite(C) WBC esterase (U) time/item (mg/dL) (mg/dL) (mg/dL) (*)|
|(*) 1040511 [0906] - ≦1.5 3+ - - Color Turbidity time/item (*)   |
|(*) 1040511 [0906] Dark Yellow 2+ *********檢驗室:HE***********  |
|群組:CBC+PLT WBC RBC HB HCT MCV time/item (k/μL) (M/μL) (g/dL)   |
|(%) (fL) 1040420 [0846] 3.28 2.89 10.3 29.1 100.7 MCH MCHC PLT   |
|RDW-CV Retic. time/item (pg) (g/dL) (k/μL) (%) (%) 1040420 [0846]|
|35.6 35.4 113 18.8 3.49 PS Retic.No. IRF time/item () (10^4/μL)  |
|(%) 1040420 [0846] - 10.09 26.8 （僅供參考） 群組:WBC D/C Blast  |
|Promyl. Myelo. Meta Band time/item (%) (%) (%) (%) (%) 1040420   |
|[0846] 0.0 0.0 0.0 0.0 0.0 Seg Eos. Baso. Mono. Lym. time/item   |
|(%) (%) (%) (%) (%) 1040420 [0846] 58.5 1.2 0.3 11.0 29.0        |
|Aty.Lym. PlasmaCell Normobl. PS time/item (%) (%) () () 1040420  |
|[0846] 0.0 0.0 0 - *********檢驗室:BC*********** 群組:General    |
|BioChemistry Alb TP T-BIL AST ALT time/item (g/dL) (g/dL) (mg/dL)|
|(U/L) (U/L) 1040420 [0846] 3.8 6.5 1.99 41 22 ALP GGT UN CRE Na  |
|time/item (U/L) (U/L) (mg/dL) (mg/dL) (mmol/L) 1040420 [0846] 72 |
|219 14.5 1.0 138 K Cl Ca time/item (mmol/L) (mmol/L) (mmol/L)    |
|1040420 [0846] 3.6 104 2.14 群組:DM GLU AC time/item (mg/dL)     |
|1040420 [0846] 101 *********檢驗室:CT*********** 群組:PT PT PT   |
|INR time/item (sec) () 1040420 [0846] 10.3 0.95 群組:PTT PTT     |
|time/item (sec) 1040420 [0846] 25.6 群組:Other Test Mixed APTT   |
|time/item (sec) 1040420 [0846] 25.6(imm.)/2 5.9(1hr) *********檢 |
|驗室:OP*********** 群組:SEDIMENT RBC (S) WBC (S) Epith (S) Cast  |
|(S) Crystal (S) time/item (/HPF) (/HPF) (/HPF) (/LPF) (*) 1040420|
|[0907] 2-5 0-2 0-2 - - Bacteria Mucus(S) Others (S) time/item (*)|
|(*) (*) 1040420 [0907] 3+ - - 群組:MULTISTIX Sp. Gr.(C) pH       |
|Protein(C) Glu.(C) Ketone body (U) time/item (*) (*) (mg/dL)     |
|(mg/dL) (*) 1040420 [0907] 1.022 6.0 200 ( 2+ ) - - O.B.(C)      |
|Urobil.(C) Bil.(C) Nitrite(C) WBC esterase (U) time/item (mg/dL) |
|(mg/dL) (mg/dL) (*) (*) 1040420 [0907] - 3.0 - - - Color         |
|Turbidity time/item (*) (*) 1040420 [0907] Dark Yellow 2+        |
|檢查紀錄(Examination Report)                                     |
|nil                                                              |
|影像報告(Imaging Report)                                         |
|CT With/Without Contrast-Chest 醫令: CT With/Without             |
|Contrast-Chest 報告醫師: 王甄 影像時間: 2015/05/01 14:44         |
|(33072B2M) 發報告時間: 2015/05/04 15:05 CT of chest without and  |
|with iv contrast shows: 1. comparison: 2015/3/20 CT. 2. right    |
|Port-A insertion. hypodense lesion at left thyroid. LN at        |
|mediastinum, stable. atherosclerotic change of aorta. a 1cm LN at|
|right cardiophrenic angle (SE5/IM48), larger 3. fibrotic change  |
|in bilateral lungs. tiny faint nodule in RLL (SE5 IM36), stable. |
|4. subsegmental atelectasis at RML, LUL lingular. bronchiectasis |
|in bilateral lungs. also suggest correlate with abdominal CT     |
|report. CT With/Without Contrast-Pelvis 醫令: CT With/Without    |
|Contrast-Pelvis 報告醫師: 黃旭辰 影像時間: 2015/05/01 14:44      |
|(33072B5M) 發報告時間: 2015/05/03 17:03 Abdomen,Pelvis CT        |
|without/with enhancement showed: > wall thickening with          |
|transmural enhancement at gastric antrum, compatible with gastric|
|cancer. > perigastric and paraaortic lymphadenopathy.            |
|lymphadenopathy at hepatic hilum with biliary dilatation. >      |
|cirrhosis. multiple liver tumors, suspect metastases. increased  |
|in size and number as compared with previous CT on 2015/3/20. >  |
|right adrenal metastases, enlarged. > gallstones. > bilateral    |
|renal cysts. > no definite lesion in spleen, pancreas, and left  |
|adrenal gland. > no ascites. > degenerative change of the spine  |
|with marginal spur formation. (Please correlate with the report  |
|of other body parts.) CT With/Without Contrast-Abdomen 醫令: CT  |
|With/Without Contrast-Abdomen 報告醫師: 黃旭辰 影像時間:         |
|2015/05/01 14:44 (33072B3M) 發報告時間: 2015/05/03 17:03         |
|Abdomen,Pelvis CT without/with enhancement showed: > wall        |
|thickening with transmural enhancement at gastric antrum,        |
|compatible with gastric cancer. > perigastric and paraaortic     |
|lymphadenopathy. lymphadenopathy at hepatic hilum with biliary   |
|dilatation. > cirrhosis. multiple liver tumors, suspect          |
|metastases. increased in size and number as compared with        |
|previous CT on 2015/3/20. > right adrenal metastases, enlarged. >|
|gallstones. > bilateral renal cysts. > no definite lesion in     |
|spleen, pancreas, and left adrenal gland. > no ascites. >        |
|degenerative change of the spine with marginal spur formation.   |
|(Please correlate with the report of other body parts.)          |
|病理報告(Pathology Report)                                       |
|T1300335 S1318218 Stomach,stated as upper body to                |
|antrum,endoscopic biopsy,adenocarcinoma S1318582 Stomach,stated  |
|as upper body to antrum,endoscopic biopsy,adenocarcinoma         |
|(Her-2/Neu 3+/3+), S1406455 Stomach,antrum,endoscopic            |
|biopsy,severe dysplasia at least, T1400072                       |
|臆斷(Tentative Diagnosis)                                        |
|1. Metastatic gastric cancer, adenocarcinoma, intestinal type,   |
|Borrmann type III, moderately differentiated, with liver         |
|metastasis, stage IV, non-resectable, cT4N2M1, HER2/Neu 3+/3+    |
|with increasing Ki-67 activity, p53 negative, status post        |
|palliative chemotherapy cisplatin + capecitabine (IV)            |
|(2013/5/28-2013/7/30), progressive disease, status post phase    |
|II/III study with TDM1 (VIII) (2013/8/30-2014/1/24), partial     |
|response (PR) then later with progressive disease (PD), status   |
|post LJM716+ Herceptin (VIII) (2014/2/25-2014/9/30), partial     |
|response (PR) then PD later, under ASLAN001 plus Cisplatin and   |
|Capecitabine (VI, 2014/10/22~ 2015/03/11), with obstructive      |
|jaundice 2. Anemia 3. Paraneoplastic syndrome with elevated ACTH |
|level                                                            |
|醫療需求與治療計畫(Medical Needs and Care Plan)                  |
|*yellowish skin for one week S: yellowish skin for one week O:   |
|PE: icteric(+) Lab: HB:8.6 g/dL WBC:9.72 k/μL PLT:235 k/μL       |
|T-BIL:11.45 mg/dL ALT:69 U/L CRE:1.1 mg/dL PT:14.2 sec PT        |
|INR:1.34 PTT:29.2 sec C+A+P CT (2015/05/01): gastric cancer with |
|enlarged abdominal lymphadenopathy, liver and right adrenal      |
|metastases. Biliary dilatation A: Metastatic gastric cancer,     |
|adenocarcinoma, intestinal type, Borrmann type III, moderately   |
|differentiated, with liver metastasis, stage IV, non-resectable, |
|cT4N2M1, HER2/Neu 3+/3+ with increasing Ki-67 activity, p53      |
|negative, status post palliative chemotherapy cisplatin +        |
|capecitabine (IV) (2013/5/28-2013/7/30), progressive disease,    |
|status post phase II/III study with TDM1 (VIII)                  |
|(2013/8/30-2014/1/24), partial response (PR) then later with     |
|progressive disease (PD), status post LJM716+ Herceptin (VIII)   |
|(2014/2/25-2014/9/30), partial response (PR) then PD later, under|
|ASLAN001 plus Cisplatin and Capecitabine (VI, 2014/10/22~        |
|2015/03/11), with obstructive jaundice P: 1. Arrange PTCD        |
|placement 2. Monitor vital signs and clinical condition 3.       |
|Supportive care 4. May arrange family meeting after then         |
|Treatment Goal: complete PTCD 【Oncology Summary】 【Initial     |
|presentation】 2013/4 progressive poor appetite and early satiety|
|【Definite Diagnosis and disease extent】 2013/5/6 Abdominal     |
|echo: an echogenic lesion 3.5cm near the pancreatic head 2013/5/6|
|panendoscopy: a protruding mass over 5cm with ulceration at      |
|gastric antrum posterior wall extended to lower gastric body     |
|2013/5/6 biopsy: gastric adenocarcinoma, intestinal type,        |
|moderately differentiated, Bormann type 3 2013/5/6 Abdominal CT: |
|advanced gastric tumor, lower body and antrum, with extraserosal |
|invasion, multiple regional and paraaortic lymphadenopathy,      |
|multiple liver metastasis and suspecting local invasion of       |
|pancreatic head. 2013/05/20 Panendoscopy: fungating tumors,      |
|easily touch bleeding, from upper body to antrum, causing poor   |
|expansion of stomach and luminal stenosis 2013/05/20 Biopsy:     |
|adenocarcinoma, Her-2/Neu 3+/3+, increasing ki-67 activity and   |
|p53 negative. *Gastric cancer, cT4N2M1, HER2/Neu 3+/3+ with      |
|increasing Ki-67 activity, p53 negative 【Treatment course,      |
|effect and side effect】 Tx:2013/5/28-2013/8/2                   |
|Capecitabine+Cisplatin (IV) {Cisplatin 106mg on D1; Xeloda 2# po |
|BID 14 days every Q3W} 2013/8/7 abdominal CT: disease progression|
|with right adrenal meta and multiple lymph nodes metastasis(upper|
|abdomen and bilateral paraaortic areas)-->PD!!                   |
|Tx:2013/8/29-2014/1/24 Phase II/III trial with TDM1 (I-VIII)     |
|{TDM-1 255mg in NS 250ml IF 30mins on D1, every Q3W} ◎ Effect:   |
|Subsequent CT during the chemotherapy was stationary. 2014/1/10  |
|CT scan: advanced gastric cancer with prominent LAPs, liver and  |
|right adrenal metastases; the liver metastases are enlarged in   |
|size. ＊ CEA level was elevated to 611.6 ng/ml--> PD!! 2014/2/11 |
|CT: showed abnormal thickening and enhancing wall is noted from  |
|the lower body, antrum to the duodenal bulb; prominent LAPs are  |
|noted in the upper abdomen and bilateral paraaortic areas;       |
|compared with prior CT 2014/01/10 study, the LNs are slightly    |
|enlarged, esp. the LN between the SMA and aorta (arrow, key      |
|images), from 14.7 mm (CT 2014/01/10) to the 20.6 mm (CT         |
|2014/02/11). Tx:2014/2/25-2014/9/30 LJM716+Herceptin (VIII)      |
|{LJM716 2800mg on D1.D8.D15.D22; Herceptin 280mg on D1. D8. D15. |
|D22} ** Side effect: fever up to 38 degree without chills or     |
|toxic signs, grade I-II diarrhea and grade I anorexia ** Effect: |
|CT on 20114/4/16, 2014/5/14, 2014/6/11 showed gastric cancer with|
|liver and adrenal metastases. Abdominal lymphadenopathy=> stable |
|disease 2014/8/6 and 2014/10/01 CT: gastric cancer with liver and|
|adrenal metastases. Abdominal lymphadenopathy. The hepatic tumor |
|(S2) and right adrenal metastatic tumor enlarged                 |
|Tx:2014/10/22~2015/2/4: Phase I trial ASLAN001 plus Cisplatin and|
|Capecitabine (I~V) {ASLAN001 (100 mg/1tab) 4 tabs PO BID on      |
|D1-D21 before Xeloda ; Capecitabine (500 mg/tab) 7 tab PO AS     |
|ORDER 9AM 4tabs PO QD; 6PM 3tabs PO QN (after ASLAN) on D1-D14;  |
|Cisplatin (80mg/m2) IF 2hrs on D1} Side effect: grade I asthenia,|
|diarrhea, mucositis,neutropenia dizziness and exertional dyspnes |
|2015/05 Obstructive jaundice                                     |
|出院規劃(Discharge Planning)                                     |
|管路留置狀況:無 日常生活功能分數：85                             |
|預期出院後居住場所：與家人同住 預期出院後主要照顧者：配偶 兒子   |
|女兒 出院規劃收案篩檢：一般病患                                  |
|主治醫師評論(VS Comments)                                        |
|I agree with the assessment made by the resident.                |
|醫師姓名                                                         |
|葉坤輝 主治醫師                                                  |

